DUCO
6.6.2017 09:03:10 CEST | Business Wire | Press release
Duco , the global provider of self-service data normalization and reconciliation services, today gave an update on its year-end results. Highlights include well over 100% growth in annually recurring revenue (ARR), a 50% increase in new clients, and significant development of the firm’s flagship reconciliation platform Duco Cube . Alongside this, Duco increased its footprint in New York and London, adding key senior management and personnel focused on research and development, client services and commercial expansion. By using Duco Cube, clients have saved over 5000 man hours per day in manual reconciliation time.
Demand for Duco Cube was driven by firms wanting to reduce costs, eliminate manual controls and address data challenges with legacy systems. Business in the UK and Europe saw growth due to regulatory requirements for EMIR, MiFID and the upcoming MiFID II , alongside supporting system migration activities. US growth was fueled by take-up in listed derivatives and the buy side. At the macro level, Duco benefitted from Software as a Service (SaaS) platforms becoming a mainstream option for the financial services industry.
The company extended its strategic agreements with several existing clients and made a number of key wins across global banks, brokers and buy side firms. In addition, Duco expanded into new industry verticals, signing a major international distribution agreement with CME Group, as well as new commercial deals with fund administrators and payments firms. The company also extended its global support structure, setting up a data center in Luxembourg following the deployment of Duco Cube for Societe Generale Bank & Trust. This continues to fuel Duco’s investment and international expansion strategy.
Christian Nentwich, CEO of Duco, said: “We have had yet another strong year and Duco is well positioned for further growth. As cost pressures, upcoming regulation and the search for efficiency continue to shape the industry, there is an ongoing shift from legacy processes to using agile, quick-to-deploy technology. We continue to set the standard in this space with a SaaS-based platform that’s live in 24 hours from contract signature, with return on investment in 30 days. Only Duco provides a self-service reconciliation tool that truly puts business users in control.”
About Duco
Duco’s mission is to make managing data easy. As the market leader in self-service reconciliation, Duco empowers users to deal with complex data in a fraction of the time required by traditional systems. New clients are live in 24 hours, with reconciliations in production in 7 days and return on investment in 30 days. Customers include international banks, brokers, exchanges, hedge funds, asset managers, fund administrators, payments companies and corporates. Headquartered in London, with offices in New York and Luxembourg, Duco serves clients throughout Europe, the United States, Africa, Asia, the Middle East and Australia.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606005125/en/
Contact:
Duco
Chris Peacock
+44 (0)203 111 9294
press@du.co
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom